Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joel Villegas

Internal Medicine Bourbonnais, IL Medical Doctor

NPI 1518063205 CMS profile 340552

370 Larry Power Rd, Suite 2, Bourbonnais, IL 60914

Open in the dashboard

General payments

$9,204

574 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joel Villegas of Bourbonnais, IL is reported in the CMS Open Payments database as having received $9,204 across 574 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,325 68
2024 General $1,379 78
2023 General $1,607 110
2022 General $1,420 84
2021 General $1,259 88
2020 General $1,006 65
2019 General $1,208 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Villegas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joel Villegas were reported at $1,325. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joel Villegas Internal Medicine median Middle half National median
2019 $1,208 $159 $48–$570 $163
2020 $1,006 $119 $33–$402 $114
2021 $1,259 $135 $37–$521 $132
2022 $1,420 $141 $42–$496 $149
2023 $1,607 $149 $45–$519 $160
2024 $1,379 $154 $47–$537 $164
2025 $1,325 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,231 83 payments
  2. AbbVie, Inc. $1,065 92 payments
  3. AstraZeneca Pharmaceuticals LP $956 52 payments
  4. Lilly USA, LLC $738 46 payments
  5. GlaxoSmithKline, LLC. $704 44 payments
  6. Pfizer Inc. $672 36 payments
  7. Amgen Inc. $644 42 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $443 23 payments
  9. Mylan Specialty L.P. $245 14 payments
  10. Allergan Inc. $213 19 payments
  11. Other $2,293 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,197 573 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $748 51 payments
  2. TRELEGY ELLIPTA $595 39 payments
  3. FARXIGA $431 20 payments
  4. NURTEC ODT Pain $420 21 payments
  5. UBRELVY $399 45 payments
  6. Prolia $373 25 payments
  7. LINZESS $373 26 payments
  8. EVENITY $361 24 payments
  9. NURTEC ODT Primary Care $318 20 payments
  10. ZAVZPRET $317 16 payments
  11. Other $8,381 490 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 112 drugs

Part D claims

6,265

Median for Internal Medicine: 777

Drug cost

$564,838

Median for Internal Medicine: $73,373

Branded share of claims

22.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 148 $149,602
Mounjaro Tirzepatide Brand 71 $79,102
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $55,716
Farxiga Dapagliflozin Propanediol Brand 50 $36,879
Januvia Sitagliptin Phosphate Brand 29 $32,300
Tresiba Flextouch U-200 Insulin Degludec Brand 35 $27,880
Tresiba Flextouch U-100 Insulin Degludec Brand 47 $24,562
Trulicity Dulaglutide Brand 20 $20,357
Eliquis Apixaban Brand 25 $16,551
Jardiance Empagliflozin Brand 18 $15,322

The 10 drugs with the highest cost, of 112 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$86,662

Of which drugs: $5,235

Medicare patients

385

Average age 74

Services billed

1,263

195 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 33%
Diabetes 32%
Chronic kidney disease 19%
Heart failure 18%
Atrial fibrillation 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 35 35 $2,864
Vaccine for influenza for injection into muscle 90662 Office 11 11 $900

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $104
$104 148 —
VRAYLAR
  • AbbVie, Inc. $86
$86 — —
MOUNJARO
  • Lilly USA, LLC $81
$81 71 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $81
$81 50 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $56
  • PFIZER INC. $13
$69 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

574 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record